# Exenatide

> Exenatide is a synthetic version of exendin-4, a peptide originally identified in the saliva of the Gila monster lizard, and was the first GLP-1 receptor agonist approved for type 2 diabetes. It is available in an immediate-release, twice-daily formulation and an extended-release, once-weekly formulation using microsphere technology. Both forms are prescription-only adjuncts to diet and exercise for glycemic control and are typically used when metformin or other oral agents provide insufficient control. It is not approved as a weight-loss treatment on its own, though weight reduction is a common secondary effect.

- URL: https://www.lifeconverted.com/peptides/exenatide
- Also known as: Byetta, Bydureon, Exendin-4
- Primary category: Other & Clinical
- Effectiveness rank: #12 in Weight Management; #18 in Other & Clinical
- Evidence level: Well studied
- Route: Subcutaneous (Immediate-release form injected within 60 minutes before a meal; extended-release form injected once weekly regardless of meals.)
- Dose range: 5-2,000 mcg
- Dose tiers: low 5 mcg; moderate 10 mcg; high 2000 mcg
- Half-life: Approximately 2.4 hours for the immediate-release form; the extended-release formulation provides sustained exposure over about 10 weeks due to slow release from injected microspheres
- Timing: Before meals
- Cycle: Continuous ongoing use as part of a diabetes treatment regimen on, Reassessed if glycemic targets are not met after an adequate trial period off
- Storage: Refrigerate unopened pens/vials at 2-8°C; the immediate-release pen in use may be kept below 25°C for up to 30 days; extended-release kits are reconstituted immediately before injection and not stored once mixed.

## Mechanism of action

Exenatide activates GLP-1 receptors on pancreatic beta cells, enhancing glucose-dependent insulin secretion while suppressing glucagon secretion in a glucose-dependent manner, reducing the risk of hypoglycemia from this mechanism alone. It also slows gastric emptying and promotes satiety through central nervous system pathways. Because it is not a substrate for the DPP-4 enzyme that rapidly degrades native GLP-1, it has a longer duration of action than the endogenous hormone.

## Reported benefits

- Improves post-meal and fasting glucose control in type 2 diabetes
- Glucose-dependent mechanism carries lower intrinsic hypoglycemia risk than sulfonylureas
- Extended-release formulation allows once-weekly dosing
- Associated with modest weight reduction in many patients

## Reported side effects

- Nausea and vomiting, most common when starting therapy
- Injection site nodules, particularly with the extended-release microsphere formulation
- Risk of pancreatitis
- Increased hypoglycemia risk when combined with sulfonylureas or insulin
- Rare risk of renal impairment

## Common protocols

- Byetta twice-daily immediate-release regimen for type 2 diabetes
- Bydureon once-weekly extended-release regimen for type 2 diabetes

## Stacking notes

Not recommended in combination with other GLP-1 receptor agonists or DPP-4 inhibitors; requires dose reduction of concurrent sulfonylureas or insulin to reduce hypoglycemia risk.

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer